Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) saw some unusual options trading activity on Wednesday. Stock traders bought 1,392 call options on the stock. This is an increase of approximately 633% compared to the typical daily volume of 190 call options.

Several equities analysts recently commented on the stock. ValuEngine lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Wells Fargo & Co lowered shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price on the stock. in a report on Wednesday, January 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price target (down previously from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Finally, SunTrust Banks dropped their price target on shares of Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $15.43.

Shares of Bellicum Pharmaceuticals (BLCM) opened at $5.56 on Monday. The firm has a market cap of $184.74, a price-to-earnings ratio of -1.86 and a beta of 0.70. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals has a 12-month low of $5.02 and a 12-month high of $15.55.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.03 million. The company’s quarterly revenue was up 18.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.66) EPS. equities research analysts expect that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.

In related news, CFO Alan A. Musso sold 17,117 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.33, for a total transaction of $159,701.61. Following the transaction, the chief financial officer now owns 31,585 shares of the company’s stock, valued at approximately $294,688.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Alan A. Musso sold 6,206 shares of the stock in a transaction on Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,165,145 shares of company stock worth $9,696,662. 18.77% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC purchased a new stake in Bellicum Pharmaceuticals during the 2nd quarter valued at $132,000. Commonwealth Equity Services Inc purchased a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth about $142,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth about $164,000. Nationwide Fund Advisors lifted its position in shares of Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,620 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth about $189,000. 55.24% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Bellicum Pharmaceuticals Target of Unusually Large Options Trading (BLCM)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2018/02/05/bellicum-pharmaceuticals-target-of-unusually-large-options-trading-blcm.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.